
Navega Therapeutics: Innovating non-addictive, specific, long-lasting, non-permanent gene therapy for pain.
Founded with a mission to revolutionize pain management, Navega Therapeutics is pioneering non-addictive, highly specific, and long-lasting gene therapies. The company leverages advanced zinc-finger and CRISPR-based epigenome regulation technologies to develop non-permanent gene therapies that target pain. Navega Therapeutics aims to provide innovative solutions that address the opioid crisis by offering safer alternatives for chronic pain sufferers.
Navega Therapeutics has garnered attention for its cutting-edge approach and has attracted notable investors and advisors in the biotech industry. The company's achievements include securing patents for its novel gene therapy techniques and advancing preclinical studies that demonstrate the efficacy and safety of their treatments. Navega Therapeutics is poised to make a significant impact on the field of pain management and the broader healthcare landscape by providing groundbreaking alternatives to traditional pain relief methods.

Latigo Biotherapeutics
latigobio.com

Regenxbio
regenxbio.com

Regel Therapeutics

Opsin Biotherapeutics
opsinbio.com

NabGen
nabgen.com

Intergalactic Therapeutics

Enavate Sciences

Navigen

Neurocarrus
neurocarrus.com

Code Biotherapeutics
codebiotx.com

Nvelop Therapeutics

Kriya Therapeutics

Regulonix Holding

Cargene
cargene.com

Nephrogen
Companies similar to Navega Therapeutics include Latigo Biotherapeutics, Regenxbio, Regel Therapeutics and Opsin Biotherapeutics.
Navega Therapeutics was founded in 2018.
Navega Therapeutics' headquarters is located in San Diego, CA, US.
Navega Therapeutics' most recent funding round was for $1.2M (USD) in April 2022.
As of Apr 1, 2022, Navega Therapeutics has raised a total of $7.8M (USD).
Navega Therapeutics has 10 employees as of Feb 4, 2024.